| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
NEO 376 targets multiple neurotransmitter receptors including 5-HT1 (serotonin) receptors, GABA receptors, and dopamine receptors. As a selective modulator of these receptors, it modulates serotonergic, GABAergic, and dopaminergic neurotransmission. The compound's antipsychotic activity is attributed to its modulation of these receptor systems. Its tetrahydroindolone core linked to an arylpiperazine moiety enables binding to multiple receptor targets. NEO 376 is also explored for neuroprotective and cognition-enhancing effects.
|
|---|---|
| ln Vitro |
In vitro, NEO 376 demonstrates selective modulation of 5-HT1 receptors, GABA receptors, and dopamine receptors. The compound shows antipsychotic activity in receptor binding and functional assays. It is a synthetic small-molecule modulator characterized by a tetrahydroindolone core linked to an arylpiperazine moiety. NEO 376 has been evaluated for its neuroprotective and cognition-enhancing effects in cell-based assays. Its receptor binding affinities and functional activities have been characterized in various in vitro systems.
|
| ln Vivo |
In vivo, NEO 376 is an investigational neuroprotective and cognition-enhancing compound explored for potential use in neurodegenerative diseases and age-related cognitive impairment. It shows antipsychotic activity in animal models. The compound's modulation of 5-HT1, GABA, and dopamine receptors suggests potential for treating psychiatric and neurological disorders. Further in vivo studies are ongoing to fully characterize its pharmacokinetic and pharmacodynamic properties. The compound is typically administered orally or via injection in preclinical studies.
|
| Enzyme Assay |
NEO 376 receptor binding assays involve measuring affinity for 5-HT1 receptors, GABA receptors, and dopamine receptors. Radioligand binding displacement studies are performed using membranes from cells expressing recombinant receptors. Functional modulation is assessed by measuring receptor-mediated signaling such as cAMP accumulation, calcium mobilization, or electrophysiological responses. Antipsychotic activity is assessed in relevant animal models or cell-based assays. Assays are performed in appropriate buffer systems with positive controls such as known receptor modulators. IC50 or EC50 values are calculated from dose-response curves.
|
| Cell Assay |
NEO 376 cell-based assays are conducted in cells expressing 5-HT1 receptors, GABA receptors, or dopamine receptors. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with NEO 376 at varying concentrations. Receptor activation or modulation is assessed by measuring downstream signaling such as cAMP levels, calcium mobilization, or electrophysiological responses. Cell viability is assessed by standard assays. For neuroprotection studies, cells are exposed to neurotoxic insults and protection is assessed. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
NEO 376 in vivo studies are conducted in animal models of psychiatric and neurological disorders. Animals are treated with NEO 376 via oral administration or injection. For antipsychotic studies, animal models of psychosis such as amphetamine-induced hyperactivity or prepulse inhibition are used. For neuroprotection studies, models of neurodegeneration are employed. For cognition studies, behavioral tests such as Morris water maze or novel object recognition are used. Dosing regimens are optimized based on pharmacokinetic data. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
NEO 376 (MW 357.88 g/mol, C20H24ClN3O) is a synthetic small molecule. It is soluble in DMSO (available as 10 mM solution). The compound is stable under recommended storage conditions. NEO 376 is also known as SPI-376. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies. The compound is typically used in psychiatric and neurological research.
|
| Toxicity/Toxicokinetics |
NEO 376 is generally well-tolerated in preclinical studies at therapeutic doses. The compound is a selective modulator of 5-HT1, GABA, and dopamine receptors with antipsychotic activity. Its investigational neuroprotective and cognition-enhancing properties have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| Additional Infomation |
NEO 376 (SPI-376) is a selective modulator of 5-HT1 receptors, GABA receptors, and dopamine receptors with antipsychotic activity. It is characterized by a tetrahydroindolone core linked to an arylpiperazine moiety. NEO 376 is an investigational neuroprotective and cognition-enhancing compound for neurodegenerative diseases and age-related cognitive impairment. Its molecular formula is C20H24ClN3O with a molecular weight of 357.88 g/mol. All applications are limited to non-human research use.
|
| Molecular Formula |
C20H24N3OCL
|
|---|---|
| Molecular Weight |
357.87706
|
| Exact Mass |
357.16
|
| CAS # |
496921-73-4
|
| PubChem CID |
9906770
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
547.7±50.0 °C at 760 mmHg
|
| Flash Point |
285.1±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.649
|
| LogP |
4.3
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
466
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C2=C(N(CCN3CCN(C4=CC=CC(Cl)=C4)CC3)C=C2)CCC1
|
| InChi Key |
CQSQHUPRBBCQRE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H24ClN3O/c21-16-3-1-4-17(15-16)23-12-9-22(10-13-23)11-14-24-8-7-18-19(24)5-2-6-20(18)25/h1,3-4,7-8,15H,2,5-6,9-14H2
|
| Chemical Name |
1-[2-[4-(3-chlorophenyl)piperazin-1-yl]ethyl]-6,7-dihydro-5H-indol-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~349.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7942 mL | 13.9712 mL | 27.9423 mL | |
| 5 mM | 0.5588 mL | 2.7942 mL | 5.5885 mL | |
| 10 mM | 0.2794 mL | 1.3971 mL | 2.7942 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
